DUBLIN–(BUSINESS WIRE)–The “Global
and China Monoclonal Antibody Industry Report, 2019-2025”
report has been added to ResearchAndMarkets.com’s
offering.

Global monoclonal antibody market can be presented as follows:

1. Monoclonal antibody drug market booms and is highly
concentrated with the approvals for such drugs.

Monoclonal antibody drugs have been maturing from a research target to
an improved technology, from clinical research to commercialization over
the past three decades. In recent years, the number of monoclonal
antibody drugs approved for launch proliferated, with 78 approved and
available on the market as of May 2018.

In 2017, 7 of 10 best-selling drugs worldwide were monoclonal antibody
drugs, the fastest growing segment in global bio-pharmaceutical market.
In Merck’s case, the sales of its Keytruda which was launched in 2014,
hit RMB7.171 billion in 2018 alone.

Global monoclonal antibody market has been expanding over the recent
years, with its size posting USD115.2 billion in 2018, a year-on-year
increase of 11%. As of April 2019, there have been 182 monoclonal
antibody drugs undergoing Phase III clinical trials worldwide. It is
expected that many a monoclonal antibody drug will be approved and
rolled out into the market in the forthcoming years, favoring a
ballooning market size to USD240.2 billion in 2025.

The world’s monoclonal antibody market is now almost carved up by Roche,
Johnson & Johnson, Merck, Novartis, AbbVie and Amgen. In 2018, the
global top eight monoclonal antibody drugs by sales, collectively
USD64,052 million, were HuMiRA, Herceptin, Avastin, Keytruda, Rituxan,
Remicade, Stelara and ENBREL?, with a combined 55.6% share in global
market.

2. The Chinese monoclonal antibody market has a rosy
prospect but players compete with each other fiercely.

As of April 2019, the National Medical Products Administration (NMPA) of
China has approved the roll-out of 33 antibody drugs (including fusion
protein), including 21 imported and 12 homemade products, far lower than
the volume approved by the US Food and Drug Administration (FDA). China
has quickened its pace of approving monoclonal antibody drugs led by
Opdivo and Keytruda, and projects to list them into its medical
insurance drugs catalogue, giving impetus to the expansion of the market
in the country.

China’s monoclonal antibody market developed by leaps and bounds between
2013 and 2017 at a CAGR of 15.6%, and would be worth RMB14.2 billion in
2018, 20.3% higher than in the previous year. The monoclonal antibody
market size in China will grow up to RMB120.7 billion in 2025 as more
new such drugs and biosimilar drugs are approved and launched.

In China, most monoclonal antibody drugs are at the clinical research
stage, the majority of which are biosimilar products. Among those on the
market, Sintilimab from Innovent Biologics and Toripalimab from Shanghai
Junshi Biosciences are two new monoclonal antibody drugs, and HLX01
developed by Shanghai Henlius Biotech is China’s first biosmilar. Other
monoclonal antibody developers include Biotech Pharma, Chengdu Taihe
Health Technology Group, Zhejiang Hisun Pharmaceutical, Genor Biopharma,
Beijing Shuanglu Pharmaceutical, Zhejiang Huahai Pharmaceutical, Livzon
Pharmaceutical Group, Mabpharm, Hualan Biological Engineering and Anhui
Anke Biotechnology (Group) Co., Ltd..

Companies like Innovent Biologics, Shanghai Junshi Biosciences and
Shanghai Henlius Biotech that stay ahead of others in drug approval for
launch, will have an edge over their peers in the market. But several
players’ application for production and Phase III clinical trials by a
number of companies which will then release their products under
approval, means that competition between local firms and their foreign
counterparts, between reference listed drugs (RLD) and biosimilars, will
remain tough in the Chinese monoclonal antibody market.

3. As star monoclonal antibody drug patents expire,
generic drugs will shock the market.

In the next five years, as the duration of star monoclonal antibody drug
patents draws to an end, biosimilar market will be the battlefield of
numerous pharmaceutical companies. Generic drugs for four monoclonal
antibody drugs have been approved and become available on the market in
European Union and the United States, signaling their squeeze of RLD in
the market.

4. Monoclonal antibodies with PD-1 and PD-L1 as targets
spring up.

The editorial board of the New England Journal of Medicine indicates
that the PD-1 monoclonal antibody is the best anticancer performer over
the past thirty years. Following the approval and release of Opdiva and
Keytruda, two PD-1 targeted monoclonal antibodies in 2014, PD-1/PD-L1
monoclonal antibody drugs like Tecentriq, Bavencio, Imfinzi and Libtayo
have also been brought to market.

Sales of Opdivo and Keytruda have been on the rise since their launch,
especially the later with sales of USD7,171 million in 2018, nearly
doubling the figure in the previous year. Global PD-1/PD-L1 monoclonal
antibody market size reached as much as USD13.9 billion in 2018, and
will expectedly surge to a staggering USD57.4 billion in 2025.

The report highlights the following:

• Global monoclonal antibody industry (status quo, market size, market
  structure, competitive landscape and development prospects);
• China’s monoclonal antibody industry (status quo, market size, market
  segments, competitive pattern and development outlook);
• Six foreign and nineteen Chinese monoclonal antibody companies
  (profile, operation and monoclonal antibody business).

Key Topics Covered

1. Overview of Monoclonal Antibody Industry

1.1 Definition

1.2 Classification

1.3 Technological Development

2. Overview of Global Monoclonal Antibody Industry

2.1 Status Quo

2.2 Market Size

2.3 Market Structure

2.4 Competition Pattern

2.5 Development Prospect and Prediction

2.5.1 New Monoclonal Antibody Drugs Will Be Approved and Available on
the Market Successively

2.5.2 Patents for Star Monoclonal Antibody Drugs Expire and Generic
Drugs Hit the Market

2.5.3 Monoclonal Antibody Taking PD-1 and PD-L1 as the Targets Is a
Rising Star

3. Chinese Monoclonal Antibody Market

3.1 Status Quo

3.2 Market Size

3.3 Market Segments

3.3.1 Rituximab (Mabthera)

3.3.2 Bevacizumab (Avastin)

3.3.3 Trastuzumab (Herceptin)

3.3.4 Adalimumab (Humira)

3.3.5 Omalizumab

3.3.6 Cetuximab

3.3.7 Infliximab

3.4 Competition Pattern

3.5 Development Prospect

3.5.1 Good Prospects of Monoclonal Antibody Market

3.5.2 Rapid Expansion of PD-1 & PD-L1 Market

3.5.3 Vigorous Development of Monoclonal Antibody Biosimilar Drug Market

4. Key Foreign Monoclonal Antibody Agent Enterprises

4.1 Roche Pharmaceuticals

4.1.1 Profile

4.1.2 Operation

4.1.3 Revenue Structure

4.1.4 R&D and Investment

4.1.5 Monoclonal Antibody Business (Genentech)

4.1.6 Business in China

4.2 Johnson & Johnson

4.3 Merck & Co Inc.

4.4 Novartis

4.5 AbbVie

4.6 Amgen

5. Key Chinese Monoclonal Antibody Agent Enterprises

5.1 BIOTECH Pharmaceutical Co. Ltd.

5.1.1 Profile

5.1.2 R&D and Production

5.1.3 Monoclonal Antibody Business

5.2 Chengdu Taihe Health Technology Group Inc. Ltd.

5.3 Shanghai Medipharm Biotech Co. Ltd.

5.4 Zhejiang Hisun Pharmaceutical Co. Ltd.

5.5 Yunnan Walvax Biotechnology Co. Ltd.

5.6 Shanghai Fosun Pharmaceutical (Group) Co. Ltd.

5.7 Beijing SL Pharmaceutical Co. Ltd.

5.8 Zhejiang Huahai Pharmaceutical Co. Ltd.

5.9 Livzon Pharmaceutical Group Inc.

5.10 Mabpharm Limited

5.11 Hualan Biological Engineering Inc.

5.12 Anhui Anke Biotechnology (Group) Co. Ltd.

5.13 Innovent Biologics Inc.

5.14 Shanghai Junshi Biosciences Co. Ltd.

5.15 Hengrui Medicine Co. Ltd.

5.16 Changchun High and New Technology Industries (Group) Inc.

5.17 Guilin Sanjin Pharmaceutical Co. Ltd.

5.18 Shenzhen Main Luck Pharmaceuticals Inc.

5.19 3SBio Group

For more information about this report visit https://www.researchandmarkets.com/r/seq0px

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology,
Biopharmaceuticals

DUBLIN–(BUSINESS WIRE)–The “Global
and China Monoclonal Antibody Industry Report, 2019-2025”
report has been added to ResearchAndMarkets.com’s
offering.

Global monoclonal antibody market can be presented as follows:

1. Monoclonal antibody drug market booms and is highly
concentrated with the approvals for such drugs.

Monoclonal antibody drugs have been maturing from a research target to
an improved technology, from clinical research to commercialization over
the past three decades. In recent years, the number of monoclonal
antibody drugs approved for launch proliferated, with 78 approved and
available on the market as of May 2018.

In 2017, 7 of 10 best-selling drugs worldwide were monoclonal antibody
drugs, the fastest growing segment in global bio-pharmaceutical market.
In Merck’s case, the sales of its Keytruda which was launched in 2014,
hit RMB7.171 billion in 2018 alone.

Global monoclonal antibody market has been expanding over the recent
years, with its size posting USD115.2 billion in 2018, a year-on-year
increase of 11%. As of April 2019, there have been 182 monoclonal
antibody drugs undergoing Phase III clinical trials worldwide. It is
expected that many a monoclonal antibody drug will be approved and
rolled out into the market in the forthcoming years, favoring a
ballooning market size to USD240.2 billion in 2025.

The world’s monoclonal antibody market is now almost carved up by Roche,
Johnson & Johnson, Merck, Novartis, AbbVie and Amgen. In 2018, the
global top eight monoclonal antibody drugs by sales, collectively
USD64,052 million, were HuMiRA, Herceptin, Avastin, Keytruda, Rituxan,
Remicade, Stelara and ENBREL?, with a combined 55.6% share in global
market.

2. The Chinese monoclonal antibody market has a rosy
prospect but players compete with each other fiercely.

As of April 2019, the National Medical Products Administration (NMPA) of
China has approved the roll-out of 33 antibody drugs (including fusion
protein), including 21 imported and 12 homemade products, far lower than
the volume approved by the US Food and Drug Administration (FDA). China
has quickened its pace of approving monoclonal antibody drugs led by
Opdivo and Keytruda, and projects to list them into its medical
insurance drugs catalogue, giving impetus to the expansion of the market
in the country.

China’s monoclonal antibody market developed by leaps and bounds between
2013 and 2017 at a CAGR of 15.6%, and would be worth RMB14.2 billion in
2018, 20.3% higher than in the previous year. The monoclonal antibody
market size in China will grow up to RMB120.7 billion in 2025 as more
new such drugs and biosimilar drugs are approved and launched.

In China, most monoclonal antibody drugs are at the clinical research
stage, the majority of which are biosimilar products. Among those on the
market, Sintilimab from Innovent Biologics and Toripalimab from Shanghai
Junshi Biosciences are two new monoclonal antibody drugs, and HLX01
developed by Shanghai Henlius Biotech is China’s first biosmilar. Other
monoclonal antibody developers include Biotech Pharma, Chengdu Taihe
Health Technology Group, Zhejiang Hisun Pharmaceutical, Genor Biopharma,
Beijing Shuanglu Pharmaceutical, Zhejiang Huahai Pharmaceutical, Livzon
Pharmaceutical Group, Mabpharm, Hualan Biological Engineering and Anhui
Anke Biotechnology (Group) Co., Ltd..

Companies like Innovent Biologics, Shanghai Junshi Biosciences and
Shanghai Henlius Biotech that stay ahead of others in drug approval for
launch, will have an edge over their peers in the market. But several
players’ application for production and Phase III clinical trials by a
number of companies which will then release their products under
approval, means that competition between local firms and their foreign
counterparts, between reference listed drugs (RLD) and biosimilars, will
remain tough in the Chinese monoclonal antibody market.

3. As star monoclonal antibody drug patents expire,
generic drugs will shock the market.

In the next five years, as the duration of star monoclonal antibody drug
patents draws to an end, biosimilar market will be the battlefield of
numerous pharmaceutical companies. Generic drugs for four monoclonal
antibody drugs have been approved and become available on the market in
European Union and the United States, signaling their squeeze of RLD in
the market.

4. Monoclonal antibodies with PD-1 and PD-L1 as targets
spring up.

The editorial board of the New England Journal of Medicine indicates
that the PD-1 monoclonal antibody is the best anticancer performer over
the past thirty years. Following the approval and release of Opdiva and
Keytruda, two PD-1 targeted monoclonal antibodies in 2014, PD-1/PD-L1
monoclonal antibody drugs like Tecentriq, Bavencio, Imfinzi and Libtayo
have also been brought to market.

Sales of Opdivo and Keytruda have been on the rise since their launch,
especially the later with sales of USD7,171 million in 2018, nearly
doubling the figure in the previous year. Global PD-1/PD-L1 monoclonal
antibody market size reached as much as USD13.9 billion in 2018, and
will expectedly surge to a staggering USD57.4 billion in 2025.

The report highlights the following:

• Global monoclonal antibody industry (status quo, market size, market
  structure, competitive landscape and development prospects);
• China’s monoclonal antibody industry (status quo, market size, market
  segments, competitive pattern and development outlook);
• Six foreign and nineteen Chinese monoclonal antibody companies
  (profile, operation and monoclonal antibody business).

Key Topics Covered

1. Overview of Monoclonal Antibody Industry

1.1 Definition

1.2 Classification

1.3 Technological Development

2. Overview of Global Monoclonal Antibody Industry

2.1 Status Quo

2.2 Market Size

2.3 Market Structure

2.4 Competition Pattern

2.5 Development Prospect and Prediction

2.5.1 New Monoclonal Antibody Drugs Will Be Approved and Available on
the Market Successively

2.5.2 Patents for Star Monoclonal Antibody Drugs Expire and Generic
Drugs Hit the Market

2.5.3 Monoclonal Antibody Taking PD-1 and PD-L1 as the Targets Is a
Rising Star

3. Chinese Monoclonal Antibody Market

3.1 Status Quo

3.2 Market Size

3.3 Market Segments

3.3.1 Rituximab (Mabthera)

3.3.2 Bevacizumab (Avastin)

3.3.3 Trastuzumab (Herceptin)

3.3.4 Adalimumab (Humira)

3.3.5 Omalizumab

3.3.6 Cetuximab

3.3.7 Infliximab

3.4 Competition Pattern

3.5 Development Prospect

3.5.1 Good Prospects of Monoclonal Antibody Market

3.5.2 Rapid Expansion of PD-1 & PD-L1 Market

3.5.3 Vigorous Development of Monoclonal Antibody Biosimilar Drug Market

4. Key Foreign Monoclonal Antibody Agent Enterprises

4.1 Roche Pharmaceuticals

4.1.1 Profile

4.1.2 Operation

4.1.3 Revenue Structure

4.1.4 R&D and Investment

4.1.5 Monoclonal Antibody Business (Genentech)

4.1.6 Business in China

4.2 Johnson & Johnson

4.3 Merck & Co Inc.

4.4 Novartis

4.5 AbbVie

4.6 Amgen

5. Key Chinese Monoclonal Antibody Agent Enterprises

5.1 BIOTECH Pharmaceutical Co. Ltd.

5.1.1 Profile

5.1.2 R&D and Production

5.1.3 Monoclonal Antibody Business

5.2 Chengdu Taihe Health Technology Group Inc. Ltd.

5.3 Shanghai Medipharm Biotech Co. Ltd.

5.4 Zhejiang Hisun Pharmaceutical Co. Ltd.

5.5 Yunnan Walvax Biotechnology Co. Ltd.

5.6 Shanghai Fosun Pharmaceutical (Group) Co. Ltd.

5.7 Beijing SL Pharmaceutical Co. Ltd.

5.8 Zhejiang Huahai Pharmaceutical Co. Ltd.

5.9 Livzon Pharmaceutical Group Inc.

5.10 Mabpharm Limited

5.11 Hualan Biological Engineering Inc.

5.12 Anhui Anke Biotechnology (Group) Co. Ltd.

5.13 Innovent Biologics Inc.

5.14 Shanghai Junshi Biosciences Co. Ltd.

5.15 Hengrui Medicine Co. Ltd.

5.16 Changchun High and New Technology Industries (Group) Inc.

5.17 Guilin Sanjin Pharmaceutical Co. Ltd.

5.18 Shenzhen Main Luck Pharmaceuticals Inc.

5.19 3SBio Group

For more information about this report visit https://www.researchandmarkets.com/r/seq0px

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Biotechnology,
Biopharmaceuticals